Add-on lacosamide in brain tumor-related epilepsy. Preliminary report: Efficacy and tolerability

Aim of the study was to evaluate efficacy and tolerability of lacosamide (LCM) as add-on in brain tumor-related epilepsy (BTRE). We followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min <1 max 10 months). Mean seizure number in the last month prior to the introduction of LCM had been 15.4. At last follow-up, the mean seizure number was reduced to 1.9/month. Lacosamide mean dosage was of 332.1 mg/day (min 100 max 400 mg/day). Responder rate was 78.6%. One patient discontinued LCM because of side effects. There were no other reported side effects.